BioLineRx Entered Exclusive License Agreement To Motixafortide In Asia, Advisored By M.S.Q. Ventures; Provides $15M Upfront And Equity Investment Of $14.6M, Up To $50M In Development And Regulatory Milestones, Up To $200M In Commercial Milestones
Portfolio Pulse from Benzinga Newsdesk
BioLineRx Ltd. (BLRX) has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) for the development of motixafortide across all indications in Asia. The agreement includes a $15 million upfront payment, an equity investment of $14.6 million, up to $50 million in potential development and regulatory milestones, and up to $200 million in potential commercial milestones. The deal was facilitated by M.S.Q. Ventures.
October 31, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioLineRx's agreement with GloriaBio for the development of motixafortide in Asia could provide significant financial benefits, including upfront payment, equity investment, and potential milestone payments.
The agreement provides BioLineRx with a significant upfront payment and equity investment, as well as the potential for substantial milestone payments. This could provide a significant financial boost to the company and potentially drive its stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100